摘要
随着免疫检查点阻断疗法在多种恶性实体瘤临床治疗中取得的突破性进展,肿瘤免疫治疗开启了新时代。然而,临床实践证明该疗法的应答率低,寻找限制其应答率的关键因素成为该领域的研究重点和热点。程序性死亡受体配体2(PD-L2)是继PD-L1后发现的能与程序性死亡受体1(PD-1)结合的第2个重要配体,编码的蛋白可与PD-1结合,进而发挥抑制免疫细胞的功能。文章就PD-L2的生物学特性、在免疫调控中的作用机制及在实体瘤免疫治疗中的研究进展简要综述,为实体瘤免疫治疗提供更多理论支持。
With the breakthrough of immune checkpoint blocking therapy in the clinical treatment of a variety of malignant solid tumors,tumor immunotherapy has opened a new era.However,clinical practice has proved that the response rate of this therapy is low.Seeking for the key factors limiting its response rate has become a research hotspot in this field.Programmed death ligand 2(PD-L2)is the second important ligand binding to programmed death 1(PD-1)after programmed death ligand 1(PD-L1).The encoded protein can bind to PD-1 and then inhibit immune cells.This paper reviews the biological characteristics of PD-L2,its mechanism in immune regulation and its research progress in solid tumor immunotherapy to provide more theoretical support for solid tumor immunotherapy.
作者
张秀萍
李智勇
王志明
Zhang Xiuping;Li Zhiyong;Wang Zhiming(Department of Medical Oncology,Xiamen Branch,Zhongshan Hospital,Fudan University,Xiamen 361015,China)
出处
《肿瘤研究与临床》
CAS
2021年第9期641-644,共4页
Cancer Research and Clinic
基金
复旦大学附属中山医院厦门医院孵化课题(2020ZSXMYS03)。
